Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Availability Of Inhaled Insulin Promotes Greater Perceived Acceptance Of Insulin Therapy In Patients With Type 2 Diabetes.

N. Freemantle, L. Blonde, D. Duhot, M. Hompesch, R. Eggertsen, F. Hobbs, L. Martinez, S. Ross, B. Bolinder, E. Stridde
Published 2005 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Inhaled insulin (INH, Exubera) is under investigation for preprandial treatment of patients with type 1 and type 2 diabetes (1–3). This dry-powder insulin formulation is delivered by aerosol, permitting the noninvasive administration of rapid-acting insulin (4). Preliminary studies have shown that INH provides reproducible and effective control of glycemia (1,5–7). This randomized controlled trial examined the extent to which the availability of INH affects the perceived acceptability of insulin therapy among patients with type 2 diabetes who failed to achieve target glycemia on current therapy. Male or female participants ( n = 779) aged 35–80 years with at least 3 months duration of type 2 diabetes and a HbA1c >8%, despite current therapy, were recruited from seven countries. Permitted current therapy included dietary measures and/or oral antidiabetic agents (OADs). Patients receiving insulin injections, smokers, or those who had significant pulmonary diseases were excluded. All patients gave informed consent, and local research ethics review boards approved the study. Participants were randomly assigned to receive either educational information about the potential risks and benefits of all currently licensed treatment options only (OADs and/or subcutaneous insulin, n = 388) or information about the potential risks and benefits of licensed treatments and INH ( n = 391). …
This paper references

This paper is referenced by
Inhaled insulin—what went wrong
J. Mitri (2009)
Preferences of Patients with Diabetes Mellitus for Inhaled versus Injectable Insulin Regimens
J. Chancellor (2012)
Perfil farmacoeconómico de Exubera® en el tratamiento de la diabetes
C. Rubio-Terrés (2007)
Inhaled insulins
S. Ghosh (2007)
Glycaemic control with advanced new insulins for the treatment of diabetes
Aston Triangle (2006)
Efficacy and safety of inhaled insulin therapy.
L. Tosiello (2006)
Inhaled Insulin as alternative delivery system for subjects with diabetes – A literature review
Inhaled insulin and its effects on the lungs
E. Sarmiento (2007)
Insulin Human (rDNA Origin) Inhalation Powder
Dennis J. Cada (2006)
Needle‐free insulin: from dreams to reality
S. Bellary (2006)
Formulation and Evaluation of Insulin Dry Powder forPulmonary Delivery
Shivanand Pandey (2009)
Inhaled insulin: extending the horizons of inhalation therapy.
Vamsi P. Guntur (2007)
Inhaled biopharmaceutical drug development: nonclinical considerations and case studies
Mary Mcelroy (2013)
Review: Inhaled insulin: overcoming barriers to insulin therapy?
S. Bellary (2006)
Drug delivery systems improve Pharmaceutical profile and facilitate medication adherence
A. Wertheimer (2005)
Inhaled insulin as adjunctive therapy in subjects with type 2 diabetes failing oral agents: a controlled proof‐of‐concept study
M. Hausmann (2006)
Diabetes Mellitus: New Challenges and Innovative Therapies
C. Sena (2013)
Inhaled insulin for diabetes mellitus.
G. McMahon (2007)
First approved inhaled insulin therapy for diabetes mellitus
R. Jani (2007)
Effect of technosphere inhaled insulin on quality of life and treatment satisfaction.
M. Peyrot (2010)
Glycaemic control with advanced new insulins for the treatment of diabetes
C. Day (2006)
The role of inhaled insulin in the treatment of type 2 diabetes.
S. Davis (2008)
Inhaled human insulin: an inspiration for patients with diabetes mellitus?
M. B. Davidson (2006)
A Systematic Review of Patients’ Perspectives on the Subcutaneous Route of Medication Administration
Colin H. Ridyard (2016)
Developing a pulmonary insulin delivery system for patients with diabetes.
G. Dailey (2007)
Oral insulin: time to rewrite the textbooks.
C. Mathieu (2019)
Inhaled human insulin (Exubera®): its pharmacologic profile, efficacy and safety in the treatment of adults with diabetes mellitus
K. Schimke (2008)
Pathophysiology and treatment of patients with type 2 diabetes exhibiting failure to oral drugs
S. Efendić (2008)
Developing accurate models of the human airways
L. J. Marshall (2015)
Inhaled insulin for diabetes mellitus.
E. V. Kriegstein (2007)
Treatment of Type 2 Diabetes Mellitus: A Weighty Enigma
R. Comi (2005)
Efficacy and safety of preprandial human insulin inhalation powder versus injectable insulin in patients with type 1 diabetes
S. Garg (2006)
See more
Semantic Scholar Logo Some data provided by SemanticScholar